Navigation Links
Biondvax's Universal Flu Vaccine Receives Additional US Patent
Date:1/27/2016

NESS ZIONA, Israel, January 27, 2016 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent.

The invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple flu strains.  

Ron Babecoff, CEO of BiondVax commented, "Current flu vaccines are strain specific and are not particularly effective against circulating 'wild-type' strains due to mismatches. In fact, last year's seasonal flu vaccine was only 23% effective[1]. Conversely, our vaccine provides long-lasting and higher effectiveness against multiple flu strains."

Continued Dr. Babecoff, "Our newly approved US patent demonstrates the novel nature of our vaccine technology and strengthens our IP portfolio for many years to come."

About BiondVax Pharmaceuticals Ltd. 

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit http://www.biondvax.com .

[1] http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, BiondVax's ability to continue obtaining and maintaining intellectual property protection for our Universal Flu Vaccine, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements. 

For further information, please contact:

Company Contact
Joshua Phillipson
Business Development  Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com


'/>"/>
SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Finesse Solutions Launches Next Generation G3Lab Universal SmartControllers to Enhance Productivity in Bench Scale Cell Culture and Fermentation
2. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
3. Drug Launch, Market Activity, Appointments, and Special Meeting of Shareholders - Research Reports on Teva, Universal Health, Tenet, Allergan and Valeant
4. Universal Health Services Inc (UHS: NYS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry
5. Westone Revolutionizes Universal-Fit Ear Protection For Firearms with New DefendEar Digital Shooter
6. Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle
7. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
8. NeuroPhages NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimers Association International Conference
9. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
10. Global Medical Lifting Sling Market 2015: Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric Analysis of the $706 Million Industry
11. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/11/2019)... ... 2019 , ... SABRE , the leading brand in personal safety and ... showcase their latest and most innovative personal safety products, including the Mighty Discreet ... Summer Market 2019 (Booth #39158-UL), June 18-20 in Denver, CO. , SABRE’s ...
(Date:6/6/2019)... OAKLAND, Calif. (PRWEB) , ... June 06, 2019 , ... ... to further curtail US travel to Cuba. “This latest move is one more assault ... the island,” said Dr. Peter G. Bourne, Chair of MEDICC’s Board of Directors. ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School of Health and ... Informatics (MSHI ) degree program to address the growing need for professionals who can ... of a larger effort for SHRS to bring more graduate degrees online. The Master ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive devices—are ... patient care. Children with birth defects, soldiers with cranial injuries, conjoined twins, ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... with caregivers and dementia patients to deteriorate. , Researchers from the University ... survey with professional caregivers who care for people who have dementia and experienced ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... Miller, a quality assurance expert with more than 25 years of experience in ... Compliance for all classes of medical devices, has joined NDA Partners as an ...
(Date:6/12/2019)... ... 12, 2019 , ... In September of 2018, NVNA and Hospice (NVNA) partnered ... patient monitoring. Following its full-scale launch in March, NVNA has expanded its program with ... of 2019, NVNA has achieved an average all-cause hospital readmissions rate of 7.3% and ...
Breaking Medicine News(10 mins):